Dublin, Ireland
September 9, 2014
Arysta LifeScience Limited (“Arysta LifeScience”) today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of ordinary shares of Arysta LifeScience.
The number of shares to be offered and the price range for the offering have not been determined. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering and as representatives of the underwriters. Citigroup Global Markets Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., Nomura Securities International, Inc. and Jefferies LLC are acting as book-running managers for the offering. Piper Jaffray & Co., Macquarie Capital (USA) Inc. and Rabo Securities USA, Inc. are acting as comanagers for the offering.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10281, by phone at (866) 718-1649, or by email at prospectus@morganstanley.com; or J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (866) 803-9204.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release is being made for information purposes only in connection with the filing of a registration statement on Form F-1 with the SEC and does not constitute an offer to sell, or the solicitation of an offer to buy, securities.
Arysta LifeScience is a leading global provider of crop solutions, with expertise in agrochemical and biological products, and sales in more than 100 countries worldwide.
Topics
Species
